CSL +3.4% single-session surge at $328.55 — biotech bid or block accumulation?
CSL's +3.37% move to $328.55 is Australia's most significant single-name event Tuesday. As the ASX 200's largest healthcare constituent and a staple of super fund portfolios, CSL at this magnitude of single-session move typically follows an analyst upgrade, clinical catalyst, or institutional block trade. CSL's blood plasma business has shown consistent volume recovery; a guidance upgrade or partner licensing announcement would justify this level of appreciation. For DRP (Dividend Reinvestment Plan) investors within super funds, $328.55 vs the prior day's base sets a new cost basis — watch Wednesday's ASX pre-open filings for any regulatory disclosure that surfaces the catalyst.
Read at Motley Fool Australia ↗